News Releases

2019

Licensing
Jun.25.2019
ONO Enters into Exclusive License Agreement with Rafael Pharmaceuticals on CPI-613 (devimistat), a Cancer Metabolism Inhibitor, and Other Related Compounds (40.5KB)
R&D
Jun.25.2019
Bristol-Myers Squibb Announces Results from CheckMate -459 Study Evaluating Opdivo (nivolumab) as a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma (36.8KB)
Management / Finance
Jun.20.2019
Notice Concerning Issuance of Stock Options (Stock Acquisition Rights) (121KB)
R&D
Jun.05.2019
Bristol-Myers Squibb Announces First Presentation of Results for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Combination in Advanced Hepatocellular Carcinoma at ASCO 2019 (37.2KB)
R&D
Jun.05.2019
Five-Year Survival Observed in Longest Follow-up to Date of Advanced Melanoma Patients Treated with the Combination of Opdivo (nivolumab) and Yervoy (ipilimumab) (36.5KB)
CSR
Jun.05.2019
ONO Announces a Medium- and Long-term Environmental Vision for 2050 - Establishment of Environment Challenging ONO Vision (ECO VISION 2050) - (397KB)
Management / Finance
Jun.03.2019
Ono Announces Status of Acquisition of Own Shares (34.3KB)
Management / Finance
May.30.2019
Announcement on Acquisition and Retirement of Own Shares (36.0KB)
R&D
May.30.2019
ONO Submits Supplemental Application of Opdivo& (Nivolumab) for Indication of Unresectable Advanced or Recurrent Esophageal Cancer in Japan for a Partial Change in Approved Items of Manufacturing and Marketing Approval (49.4KB)
Corporate
May.22.2019
Ono's Statement in response to the Press Reports with respect to PD-1 Related Patents (37.0KB)
R&D
May.22.2019
Array BioPharma Announces BRAFTOVI + MEKTOVI + Cetuximab Meet Primary Endpoints of ORR and OS in Phase 3 BEACON CRC Trial Interim Analysis for the Treatment of BRAFV600E-mutant Metastatic Colorectal Cancer (36.1KB)
R&D
May.14.2019
Opdivo® (Nivolumab) Intravenous Infusion Received Additional Approvals related to Three Indications in Taiwan (104KB)
R&D
May.13.2019
Bristol-Myers Squibb Announces Phase 3 CheckMate -498 Study Did Not Meet Primary Endpoint of Overall Survival with Opdivo (nivolumab) Plus Radiation in Patients with Newly Diagnosed MGMT-Unmethylated Glioblastoma Multiforme (37.1KB)
Products
May.10.2019
Certain Media Coverage relating to Opdivo Reported on May 9 (48.0KB)
Management / Finance
May.09.2019
Notice regarding Differences between Non-Consolidated Results for the Fiscal Year Ended March 31, 2019 and Those for the Previous Fiscal Year (102KB)
Corporate
Apr.04.2019
Announcement on Candidates of Members of Board of Directors, Members of Audit & Supervisory Board and Corporate Officers (39.7KB)
R&D
Apr.03.2019
Bristol-Myers Squibb Announces Long-Term Survival Results from Pooled Analyses of Opdivo (nivolumab) in Previously-Treated Non-Small Cell Lung Cancer Patients (53.7KB)
R&D
Mar.28.2019
ONO Submits Supplemental Application of Opdivo® (Nivolumab) for Indication of MSI-H Unresectable Advanced or Recurrent Colorectal Cancer That Has Progressed Following Chemotherapy, for a Partial Change in Approved Items of Manufacturing and Marketing Approval in Japan (48.2KB)
R&D
Mar.27.2019
A selective sodium-glucose co-transporter 2 (SGLT2) inhibitor Forxiga receives additional regulatory approval on indication and dosage and administration in type-1 diabetes in Japan (115KB)
Licensing
Mar.27.2019
ONO Announces a Strategic Drug Discovery Alliance Agreement with Cancer Research UK and LifeArc for Cancer Immunotherapy (64.3KB)
R&D
Mar.26.2019
A Short-Acting Selective β1 Blocker, ONOACT® for Intravenous Infusion 50mg/150mg Approved for Additional Indication of Ventricular Arrhythmia in Japan (108KB)
R&D
Mar.19.2019
ONO Submits Supplemental Application of Kyprolis® for Intravenous Injection, a Proteasome Inhibitor, for Additional Dosage and Administration for the Treatment of Relapsed or Refractory Multiple Myeloma in Japan (40.2KB)
Licensing
Mar.18.2019
Ono Enters into Research Collaboration Agreement with twoXAR, Inc. (37.5KB)
R&D
Mar.14.2019
ONO and Novartis Pharma Receive a Supplemental Approval for Formulation with New Ingredient of Rivastach® Patch and Exelon® Patch for the Treatment of Alzheimer's Disease Dementia (40.5KB)
R&D
Mar.11.2019
BMSKK and ONO Submit Supplemental Applications of Orencia® for I.V. Infusion, Orencia® Syringe for S.C. Injection and Orencia® Autoinjector for S.C. Injection, a Selective T-cell Co-Stimulation Modulator, for Inhibition of Structural Damage of Joints in Rheumatoid Arthritis (55.7KB)
R&D
Feb.27.2019
ONO Submits an Application for Manufacturing and Marketing Approval of Opicapone (ONO-2370) for the Treatment of Parkinson's Disease Patients with Motor Fluctuations in Japan (43.6KB)
Products
Feb.26.2019
Launch of Demser® Capsule 250 mg, a Tyrosine Hydroxylase Inhibitor in Japan (83.8KB)
Products
Feb.26.2019
Launch of BRAFTOVI® Capsule 50 mg, a BRAF Inhibitor and MEKTOVI® Tablet 15 mg, a MEK Inhibitor in Japan (175KB)
CSR
Feb.25.2019
ONO Certified in 2019 as Outstanding Health and Productivity Management Organization (White 500) (138KB)
R&D
Feb.19.2019
Ono and Seikagaku Announce the Topline Results from a Phase III Confirmatory Study of ONO-5704/SI-613 in Patients with Knee Osteoarthritis in Japan (96.1KB)
R&D
Feb.15.2019
Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) Demonstrates Continued Survival Benefit at 30-Month Follow-up in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (51.8KB)
R&D
Feb.15.2019
Opdivo (nivolumab) Plus Yervoy (ipilimumab) Shows Response in Pre-Treated Patients with Metastatic Castration-Resistant Prostate Cancer (48.2KB)
Licensing
Jan.31.2019
ONO Announces a Strategic Partnership Agreement with Repare Therapeutics for a Pol-theta Inhibitor Program (108KB)
CSR
Jan.22.2019
ONO Selected by CDP as a Climate Change A List Company in 2018 (76.3KB)
R&D
Jan.18.2019
Opdivo® (Nivolumab) Intravenous Infusion Approved for Expanded Use in Non-Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy in Taiwan (71.4KB)
R&D
Jan.15.2019
European Commission Approves Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) for First-Line Treatment of Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma (47.8KB)
R&D
Jan.15.2019
Array BioPharma Announces 15.3 Months Median Overall Survival from the Safety Lead-in of the Phase 3 BEACON CRC Trial of the Combination BRAFTOVI®, MEKTOVI® and ERBITUX® in BRAF-Mutant Metastatic Colorectal Cancer (36.2KB)
R&D
Jan.10.2019
Karyopharm Announces Submission of Marketing Authorization Application to the European Medicines Agency for Selinexor for the Treatment of Patients with Penta-Refractory Multiple Myeloma (35.3KB)
R&D
Jan.09.2019
Opdivo® (Nivolumab) Demonstrates a Significant Extension in Overall Survival Versus Chemotherapy in Patients with Unresectable Advanced or Recurrent Esophageal Cancer in Phase III Clinical Study (42.4KB)
R&D
Jan.08.2019
ONO Receives Manufacturing and Marketing Approval in Japan for Demser® Capsule, a Tyrosine Hydroxylase Inhibitor, for Improvement of Status of Catecholamine Excess Secretion and its Accompanying Symptoms in Patients with Pheochromocytoma (64.7KB)
R&D
Jan.08.2019
ONO Receives a Manufacturing and Marketing Approval for BRAFTOVI® Capsule, a BRAF Inhibitor and MEKTOVI® Tablet, a MEK Inhibitor for Indication of Unresectable BRAF-Mutant Melanoma in Japan (58.3KB)
CSR
Jan.07.2019
ONO Listed in FTSE4Good Index Series and FTSE Blossom Japan Index for Socially Responsible Investment (121KB)